Skip to content

Study · Randomized controlled trial · n = 23 · 2015

3 results

Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability.

Finger EC, MacKinley J, Blair M, Oliver LD, Jesso S, Tartaglia MC, Borrie M, Wells J, Dziobek I, Pasternak S, Mitchell DG, Rankin K, Kertesz A, Boxer A

Neurology10 Dec 2014Cited by 75 (Europe PMC)

PMID25503617 (opens in a new tab)PMCIDPMC4336088 (opens in a new tab)DOI10.1212/wnl.0000000000001133 (opens in a new tab)PepBankPUB-25503617
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In patients with frontotemporal dementia, all 3 doses of intranasal oxytocin were safe and well tolerated.

    In plain wordsIn people with frontotemporal dementia, all 3 doses of oxytocin nasal spray were safe and well tolerated in this short trial.

    Peptide
    Oxytocin
    Outcome
    No significant changeSafety and tolerability at each dose
    Study

    n = 23

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    24, 48 or 72 IU twice daily · intranasal · 1 weekAs given in this study (human).

    Source sentences

    Summary
    All 3 doses of intranasal oxytocin were safe and well tolerated.
    1 context sentence
    Summary · context
    We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia (clinical…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with frontotemporal dementia, intranasal oxytocin was not significantly associated with changes in the overall neuropsychiatric inventory versus placebo.

    In plain wordsIn people with frontotemporal dementia, oxytocin nasal spray did not significantly change overall behaviour symptom scores compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeOverall neuropsychiatric inventory
    Study

    n = 23

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    24, 48 or 72 IU twice daily · intranasal · 1 weekAs given in this study (human).

    Source sentences

    Summary
    intranasal oxytocin is not significantly associated with adverse events or significant changes in the overall neuropsychiatric inventory.
    1 context sentence
    Summary · context
    We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia (clinical…
  3. 03HumanRandomized controlled trialSafety outcome

    In patients with frontotemporal dementia, intranasal oxytocin was not significantly associated with adverse events versus placebo.

    In plain wordsIn people with frontotemporal dementia, oxytocin nasal spray was not linked to more side effects than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeAdverse events
    Study

    n = 23

    Comparator
    Placebo
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    24, 48 or 72 IU twice daily · intranasal · 1 weekAs given in this study (human).

    Source sentences

    Summary
    intranasal oxytocin is not significantly associated with adverse events
    1 context sentence
    Summary · context
    We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia (clinical…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01386333

Safety Study of Intranasal Oxytocin in Frontotemporal Dementia

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sn = 23Jun 2011 to Oct 2013 (primary)

Frontotemporal Dementia

Trial pageClinicalTrials.govUpdated 4 Nov 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.